Hiroaki Kikukawa

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Pharmacological effects of tolterodine on human isolated urinary bladder

Makoto Yono, Masaki Yoshida, Yoshihiro Wada et al. · European Journal of Pharmacology · 1999 · 50 citations

Medicine, Pharmacology, Urology +6

Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder.

Yuki Wada, Masaki Yoshida, Kenichi Kitani et al. · PubMed · 1996 · 43 citations

Medicine, Pharmacology, Urology +14

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

Thomas Powles, Michiel Simon Van Der Heijden, Ying Wang et al. · Journal of Clinical Oncology · 2025 · 35 citations

Medicine, Oncology, Surgery +16

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Nobuaki Matsubara, Satsohi Nagamori, Yoshiaki Wakumoto et al. · International Journal of Clinical Oncology · 2017 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17